Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 131

face_with_colon_three This new gold rush with AI will bring new jobs for even Psychiatry and Therapists which is already leading to new bots with human like therapists in texts. This could lead to even better mental health for the global population.

“Psychotherapy is very expensive and even in places like Canada, where I’m from, and other countries, it’s super expensive, the waiting lists are really long,” Ashley Andreou, a medical student focusing on psychiatry at Georgetown University, told Al Jazeera.

“People don’t have access to something that augments medication and is evidence-based treatment for mental health issues, and so I think that we need to increase access, and I do think that generative AI with a certified health professional will increase efficiency.”

The prospect of AI augmenting, or even leading, mental health treatment raises a myriad of ethical and practical concerns. These range from how to protect personal information and medical records, to questions about whether a computer programme will ever be truly capable of empathising with a patient or recognising warning signs such as the risk of self-harm.

Read more | >

A machine learning-based method developed by a Mount Sinai research team allows medical facilities to forecast the mortality risk for certain cardiac surgery patients. The new method is the first institution-specific model for determining the risk of a cardiac patient before surgery and was developed using vast amounts of Electronic Health Data (EHR).

Comparing the data-driven approach to the current population-derived models reveals a considerable performance improvement.

Read more | >

The demo is clever, questionably real, and prompts a lot of questions about how this device will actually work.

Buzz has been building around the secretive tech startup Humane for over a year, and now the company is finally offering a look at what it’s been building. At TED last month, Humane co-founder Imran Chaudhri gave a demonstration of the AI-powered wearable the company is building as a replacement for smartphones. Bits of the video leaked online after the event, but the full video is now available to watch.

The device appears to be a small black puck that slips into your breast pocket, with a camera, projector, and speaker sticking out the top. Throughout the 13-minute presentation, Chaudhri walks through a handful of use cases for Humane’s gadget: * The device rings when Chaudhri receives a phone call. He holds his hand up, and the device projects the caller’s name along with icons to answer or ignore the call. He then has a brief conversation. (Around 1:48 in the video) * He presses and holds one finger on the device, then asks a question about where he can buy a gift. The device responds with the name of a shopping district. (Around 6:20) * He taps two fingers on the device, says a sentence, and the device translates the sentence into another language, stating it back using an AI-generated clone of his voice. (Around 6:55) * He presses and holds one finger on the device, says, “Catch me up,” and it reads out a summary of recent emails, calendar events, and messages. (At 9:45) * He holds a chocolate bar in front of the device, then presses and holds one finger on the device while asking, “Can I eat this?” The device recommends he does not because of a food allergy he has. He presses down one finger again and tells the device he’s ignoring its advice. (Around 10:55)

Chaudhri, who previously worked on design at Apple for more than two decades, pitched the device as a salve for a world covered in screens. “Some believe AR / VR glasses like these are the answer,” he said, an image of VR headsets behind him. He argued those devices — like smartphones — put “a further barrier between you and the world.”

Humane’s device, whatever it’s called, is designed to be more natural by eschewing the screen. The gadget operates on its own. “You don’t need a smartphone or any other device to pair with it,” he said.

Read more | >

(https://isbscience.org/bio/leroy-hood/) is Co-Founder, Chief Strategy Officer and Professor, at the Institute of Systems Biology (ISB) in Seattle, as well as CEO of Phenome Health (https://phenomehealth.org/), a nonprofit organization dedicated to delivering value through health innovation focused on his P4 model of health (Predictive, Preventive, Personalized and Participatory) where a patient’s unique individuality is acknowledged, respected, and leveraged for the benefit of everyone.

Dr. Hood, who is a world-renowned scientist and recipient of the National Medal of Science in 2011, co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000–2017. In 2016, ISB affiliated with Providence St. Joseph Health (PSJH) and Dr. Hood became PSJH’s Senior Vice President and Chief Science Officer.

Dr. Hood is a member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood is one of only 20 people elected to all three.

Dr. Hood received his MD from Johns Hopkins University School of Medicine and his PhD in biochemistry from Caltech.

Dr. Hood was a faculty member at Caltech from 1967–1992, serving for 10 years as the Chair of Biology. During this period, he and his colleagues developed four sequencer and synthesizer instruments that paved the way for the Human Genome Project’s successful mapping and understanding of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification.

In 1992, Dr. Hood founded and chaired the Department of Molecular Biotechnology at the University of Washington, the first academic department devoted to cross-disciplinary biology.

Continue reading “Dr. Leroy Hood, MD, Ph.D. — Co-Founder, Institute of Systems Biology (ISB); CEO, Phenome Health” | >

The adoption of AI in clinical settings has increased exponentially over the past decade, but AI models still haven’t achieved the level of ubiquity that they could within the sector.

A few years ago, a group of Mayo Clinic researchers recognized this major problem. The health system was producing a huge amount of research on AI in clinical contexts, but it was still having a hard time actually deploying those AI models at scale.

That realization led to the creation of Lucem Health, a platform for clinical AI solution deployment. The North Carolina-based startup, which launched in 2021, closed a $7.7 million Series A funding round last week.

Read more | >

A new study adds to an emerging, radically new picture of how bacterial cells continually repair faulty sections of their DNA.

Published online May 16 in the journal Cell, the report describes the behind a DNA repair pathway that counters the mistaken inclusion of a certain type of molecular building block, ribonucleotides, into genetic codes. Such mistakes are frequent in code-copying process in bacteria and other organisms. Given that ribonucleotide misincorporation can result in detrimental DNA code changes (mutations) and DNA breaks, all organisms have evolved to have a DNA repair pathway called ribonucleotide excision repair (RER) that quickly fixes such errors.

Last year a team led by Evgeny Nudler, Ph.D., the Julie Wilson Anderson Professor in the Department of Biochemistry and Molecular Pharmacology at NYU Langone Health, published two analyses of DNA repair in living E. coli cells. They found that most of the repair of certain types of DNA damage (bulky lesions), such as those caused by UV irradiation, can occur because damaged code sections have first been identified by a called RNA . RNA polymerase motors down the DNA chain, reading the code of DNA “letters” as it transcribes instructions into RNA molecules, which then direct protein building.

Read more | >

Dr. Steven Gazal, an assistant professor of population and public health sciences at the Keck School of Medicine of USC, is on a mission to answer a perplexing question: Why, despite millions of years of evolution, do humans still suffer from diseases?

As part of an international research team, Gazal has made a groundbreaking discovery. They’ve become the first to accurately pinpoint specific base pairs in the human genome that have remained unaltered throughout millions of years of mammalian evolution. These base pairs play a significant role in human disease. Their findings were published in a special Zoonomia edition of the journal Science.

Gazal and his team analyzed the genomes of 240 mammals, including humans, zooming in with unprecedented resolution to compare DNA.

Read more | >

Technology As A Force For Good In People’s Lives — Dr. Emre Ozcan, PhD, VP, Global Head of Digital Health & Walid Mehanna, Group Data Officer And Senior Vice President, Merck KGaA, Darmstadt, Germany.

EPISODE DISCLAIMER — At any time during this episode when anyone says Merck, in any context, it shall always be referring to Merck KGaA, Darmstadt, Germany.

Dr. Emre Ozcan, Ph.D. is VP, Global Head of Digital Health, at Merck KGaA, Darmstadt, Germany (https://www.emdgroup.com/en), where he brings 15+ years experience in biopharma, med-tech and healthcare consulting with experience across strategy, research, marketing, and operations in several therapeutic areas. In his current role, he holds the accountability for the design and end-to-end delivery of digital health solutions to support Merck KGaA, Darmstadt, Germany franchise strategies and shape the architecture of the offering “around the drug” including devices and diagnostics.

Prior to joining Merck KGaA, Darmstadt, Germany, Dr. Ozcan was a Junior Partner at Boston Consulting Group. He holds a BA degree from Yale University; and MPhil and PhD from Oxford University.

Walid Mehanna is Group Data Officer And Senior Vice President, Merck KGaA, Darmstadt, Germany, where he has responsibility for driving Data & Analytics strategy, implementation, architecture, governance, and culture across all its businesses.

Continue reading “Dr. Emre Ozcan & Walid Mehanna — Merck KGaA, Darmstadt, Germany — Tech As A Force For Good In Health” | >

Scientists with the Human Pangenome Reference Consortium have made groundbreaking progress in characterizing the fraction of human DNA that varies between individuals. They have assembled genomic sequences of 47 people from around the world into a so-called pangenome in which more than 99 percent of each sequence is rendered with high accuracy.

For two decades, scientists have relied on the human reference genome as a standard to compare against other genetic data. Thanks to this reference genome, it was possible to identify genes implicated in specific diseases and trace the evolution of human traits, among other things.

However, it has always been a flawed tool: 70% of its data came from a single man of predominantly African-European background whose DNA was sequenced during the Human Genome Project. Hence, it can reveal very little about individuals on this planet who are different from each other, creating an inherent bias in biomedical data believed to be responsible for some of the health disparities affecting patients today.

Read more | >